MK0752, (Notch Inhibitor)
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphoblastic, Acute, T-cell
Conditions
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
Trial Timeline
Feb 1, 2005 → Oct 1, 2006
NCT ID
NCT00100152About MK0752, (Notch Inhibitor)
MK0752, (Notch Inhibitor) is a phase 1 stage product being developed by Merck for Leukemia, Lymphoblastic, Acute, T-cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT00100152. Target conditions include Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00100152 | Phase 1 | Terminated |
Competing Products
20 competing products in Leukemia, Lymphoblastic, Acute, T-cell